Skip to main content
OpenTrials
Completed

NCT Number: NCT06129812

An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer

An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pancreatic Cancer Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Neoadjuvant Neoplasms Neoplasms by Site Pancreatic Diseases Pancreatic Neoplasms

Sex eligibility

All sexes

Study type

Observational

About this study

The 1,132 patients with resectable or borderline resectable PDAC who underwent surgery between 2007 and 2021 were retrospectively reviewed. Patients with resectable PDAC without contact of major vessels (R-no contact) (n=651), with contact of portal vein or superior mesenteric vein (PV/SMV) ≤180° (R-contact) (n=306), and borderline resectable PDAC without arterial involvement (BR-V) (n=175) were analyzed.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with resectable or borderline resectable pancreatic ductal adenocarcinoma (PDAC)
  • Between January 2007 and June 2021 at Seoul National University Hospital

Exclusion criteria

  • Patients who had borderline resectable PDAC with arterial invasion
  • Patients who received chemotherapy as initial treatment and did not undergo surgery
  • Incomplete follow-up data for analysis

Treatment and study plan

Neoadjuvant treatment

Drug

Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.

Primary outcomes

  1. Overall survival

    Time frame: From the date when biopsy results came out until the date of death from any cause or the date of the last visit, whichever came first, assessed up to 60 months

    the time from diagnosis to death from any cause or the date of the last visit

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Registry information

Official study title

An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer According to Tumor-vessel Relationship and CA 19-9 Levels

Important dates

Study start
2007
Primary completion
2021
Study completion
2021
First posted
Nov 13, 2023
Registry last updated
Nov 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.